Why the study?
Do ANP polymorphisms affect lipid levels and CAD risk in patients with familial hypercholesterolemia?
Population
83 Greek patients with familial hypercholesterolemia (FH)
Comparison
Presence of ANP polymorphisms vs Absence of these polymorphisms
Design
Cross-sectional
Authors
Loading...
No immediate implications for CAD risk assessment in familial hypercholesterolemia; leaves open ANP effects on ApoA1/HDL-C for further study.
Do ANP polymorphisms affect lipid levels and CAD risk in patients with familial hypercholesterolemia?
The ANP G664A polymorphism is associated with lower ApoA1 and HDL-C levels in patients with familial hypercholesterolemia, but does not appear to influence the risk of coronary artery disease.
Dedoussis et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: